Phase I Trial of Weekly Cabazitaxel with Concurrent Intensity Modulated Radiation and Androgen Deprivation Therapy for the Treatment of High-Risk Prostate Cancer.

Jianqing Lin,Robert B Den,Jacob Greenspan,Timothy N Showalter,Jean H Hoffman-Censits,Costas D Lallas,Edouard J Trabulsi,Leonard G Gomella,Mark D Hurwitz,Benjamin Leiby,Adam P Dicker,W Kevin Kelly

International Journal of Radiation Oncology*Biology*Physics（2020）

引用 3|浏览85

暂无评分

摘要

This is the first clinical trial of prostate cancer to report on the combination of cabazitaxel and radiation therapy. The maximum tolerated dose of concurrent cabazitaxel with radiation and androgen deprivation therapy was determined to be 6 mg/m. Despite the aggressive nature of the disease, robust biochemical control was observed.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要